HUP0002104A2 - Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0002104A2
HUP0002104A2 HU0002104A HUP0002104A HUP0002104A2 HU P0002104 A2 HUP0002104 A2 HU P0002104A2 HU 0002104 A HU0002104 A HU 0002104A HU P0002104 A HUP0002104 A HU P0002104A HU P0002104 A2 HUP0002104 A2 HU P0002104A2
Authority
HU
Hungary
Prior art keywords
group
general formula
pyrazolo
preparation
pharmaceutical compositions
Prior art date
Application number
HU0002104A
Other languages
English (en)
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Original Assignee
Astrazeneca Ab.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab. filed Critical Astrazeneca Ab.
Publication of HUP0002104A2 publication Critical patent/HUP0002104A2/hu
Publication of HUP0002104A3 publication Critical patent/HUP0002104A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)

Abstract

Atalálmány tárgyát az (I) általános képletű, új pirazolo[3,4-d]pirimidindion-származékok - ahol az (I) általános képletben aszubsztituensek főbb jelentései: R1 és R2 alkil- vagy alkenilcsoport;R3 -CHR4(CH2)nAr általános képletű csoport, amelyben n értéke 0, R4hidrogénatom, és Ar kinolil-, naftil-, adott esetben szubsztituáltbenzodioxolil- vagy fenilcsoport; W hidrogénatom, hidroxi-metil-,karboxi-, alkoxi-karbonil- vagy piridilcsoport; X vegyértékvonal vagyalkiléncsoport; és Y kénatom vagy etiléncsoport - és előállításukraszolgáló eljárás, immunszuppresszánsként való gyógyászatialkalmazásuk, hatóanyagként ezeket tartalmazó gyógyszerkészítmények,valamint ezek előállítása képezik. Ó
HU0002104A 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them HUP0002104A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds

Publications (2)

Publication Number Publication Date
HUP0002104A2 true HUP0002104A2 (hu) 2001-01-29
HUP0002104A3 HUP0002104A3 (en) 2002-03-28

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002104A HUP0002104A3 (en) 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (21)

Country Link
US (1) US6028074A (hu)
EP (1) EP0975636B1 (hu)
JP (1) JP2001520645A (hu)
KR (1) KR20010006350A (hu)
CN (1) CN1259951A (hu)
AT (1) ATE245648T1 (hu)
AU (1) AU733066B2 (hu)
BR (1) BR9808540A (hu)
CA (1) CA2286078A1 (hu)
DE (1) DE69816608T2 (hu)
EE (1) EE9900465A (hu)
HU (1) HUP0002104A3 (hu)
ID (1) ID22746A (hu)
IL (1) IL132153A0 (hu)
IS (1) IS5198A (hu)
NO (1) NO995006D0 (hu)
PL (1) PL336230A1 (hu)
SE (1) SE9701398D0 (hu)
SK (1) SK135699A3 (hu)
TR (1) TR199902538T2 (hu)
WO (1) WO1998046606A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6875786B2 (en) 2001-03-01 2005-04-05 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
EP1901701A4 (en) * 2005-05-24 2012-05-02 David M Ott BODY CARE AND MEDICAL PRODUCTS WITH JOINED SULFUR ORGANIC GROUPS
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2240028B1 (en) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
CN102238872A (zh) 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
CA2740385A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
SG171776A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
AU2009322905A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
GEP20146046B (en) * 2008-12-06 2014-02-25 Intracellular Therapies Inc Organic compounds
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
DK2411397T3 (da) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
PL2411393T3 (pl) * 2009-03-23 2014-06-30 Glenmark Pharmaceuticals Sa Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US8609693B2 (en) 2009-05-29 2013-12-17 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
IN2014MN02467A (hu) 2012-06-08 2015-07-10 Glenmark Pharmaceuticals Sa
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
ES2857567T3 (es) 2014-09-17 2021-09-29 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
WO2018015088A1 (en) * 2016-06-23 2018-01-25 F. Hoffmann-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500966A (ja) * 1981-04-22 1983-06-09 ビイク　グルデン　ロンベルク　ヒエ−ミツシエ　フアブリ−ク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピラゾロ〔３，４−ｄ〕ピリミジン、その製法及びこれを含有する医薬品
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (en) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
AU690527B2 (en) * 1992-12-17 1998-04-30 Pfizer Inc. Pyrazoles having CRF antagonist activity

Also Published As

Publication number Publication date
JP2001520645A (ja) 2001-10-30
HUP0002104A3 (en) 2002-03-28
US6028074A (en) 2000-02-22
ID22746A (id) 1999-12-09
TR199902538T2 (xx) 2000-02-21
BR9808540A (pt) 2000-05-23
IL132153A0 (en) 2001-03-19
IS5198A (is) 1999-09-27
NO995006L (no) 1999-10-14
WO1998046606A1 (en) 1998-10-22
CN1259951A (zh) 2000-07-12
EE9900465A (et) 2000-04-17
AU733066B2 (en) 2001-05-03
CA2286078A1 (en) 1998-10-22
AU7090998A (en) 1998-11-11
SE9701398D0 (sv) 1997-04-15
DE69816608T2 (de) 2004-04-15
KR20010006350A (ko) 2001-01-26
EP0975636A1 (en) 2000-02-02
NO995006D0 (no) 1999-10-14
EP0975636B1 (en) 2003-07-23
DE69816608D1 (de) 2003-08-28
PL336230A1 (en) 2000-06-19
ATE245648T1 (de) 2003-08-15
SK135699A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
HUP0002104A2 (hu) Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
HUP0300641A2 (hu) Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
SE9504661D0 (sv) New compounds
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
IL123293A (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
MY127718A (en) Dolastatin 10 derivatives.
HUP9802323A2 (hu) Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
MXPA02003199A (es) Derivados de sulfonamida farmaceuticamente activos.
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
ATE316083T1 (de) Adamantanderivate
IS6658A (is) Ný efnasambönd
DE60108236D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
FI931600A0 (fi) Pyridiner och pyridin-n-oxidderivat av diarylmetylpiperidiner eller piperaziner, och foereningar och foerfarande foer deras anvaendning
TR200001973T2 (tr) 11 ß-halojen-7alfa-ile ikame edilmiş-estratrienler, bu 11ß-halojen-7alfa-ile ikame edilmiş-estratrienleri içeren farmasötik terkiplerin üretimi için yöntem ve ilaç üretiminde kullanımları.
HUP0102602A2 (hu) Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
YU14196A (sh) Estri i amidi di-supstituisanog 1,4-piperidina, postupci za njihovo dobijanje i farmakološke kompozicije koje ih sadrže
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
EE200000048A (et) Uudsed ühendid
TR199800608A2 (en) Propanolamin t�revleri, bunlar�n �retim usul�.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции